Hospital Israelita Albert Einstein, São Paulo, Brazil.
Massachusetts General Hospital, Boston, USA.
J Robot Surg. 2024 Sep 17;18(1):341. doi: 10.1007/s11701-024-02097-0.
Robotic colectomy has been associated with comparable or improved short-term morbidity and mortality when compared to laparoscopic colectomy, including shorter length of stay. In this study, we sought to understand oncologic advantages for robotic as compared to laparoscopic colectomy in colon cancer. We analyzed the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) participant user files for all elective colon cancer cases from 1/2016 through 12/2021 performed with minimally invasive surgical techniques (robotic and laparoscopic). We calculated relative risks (RR) through Poisson Regression models and treatment effect coefficients by propensity-score match, after adjusting for age, BMI, ASA scores, mechanical and antibiotic bowel preparation, emergency surgery, race, gender, smoking status, hypertension and diabetes mellitus. Analyzed outcomes included rate of chemotherapy initiation within 90 days of surgery, number of harvested lymph nodes, any occurrence of intraoperative or postoperative blood transfusion, and the need for ostomy. During the study period, 44,745 patients underwent minimally invasive colectomy for colon cancer; 39,614 in the laparoscopic cohort and 7,831 in the robotic cohort. After adjusting for confounders, robotic colectomy was associated with a significant increase in the likelihood for initating chemotherapy within 90 days (RR 1.98, 95% CI {1.86-2.10}, p < 0.001). The robotic-treated patients had a significantly more lymph nodes harvested, a significant decrease in the need for intraperative or postoperative blood transfusion (RR 0.64, 95% CI {0.57-0.71}, p < 0.001) and a significant reduction in the need for ostomy formation (RR 0.26, 95% CI {0.22-0.30}, p < 0.001). As a retrospective and non-randomized study, residual bias and confouding variables are likely to exist. The study is also subject to coding incompleteness and inaccuracies. We also do not have additional context on potential factors that might influence time to chemotherapy. In addition, there is no information on surgeon or hospital volume, which can be associated with outcomes. Robotic colectomy for colon cancer was associated with significant improvement in the rate of chemotherapy initiation within 90 days, a significant reduction in need for blood transfusions, and a lower likelihood of receiving an ostomy when compared to laparoscopic colectomy procedures. The data reveal substantial short-term gains in oncologic outcomes for colon cancer performed with robotic techniques.
机器人结直肠切除术与腹腔镜结直肠切除术相比,短期发病率和死亡率相当或更低,包括住院时间更短。在这项研究中,我们旨在了解机器人手术与腹腔镜手术相比在结肠癌中的肿瘤学优势。我们分析了美国外科医师学会国家手术质量改进计划(NSQIP)参与者用户文件中 2016 年 1 月至 2021 年 12 月期间所有采用微创技术(机器人和腹腔镜)进行的择期结肠癌病例。我们通过泊松回归模型计算相对风险(RR),并通过倾向评分匹配计算治疗效果系数,同时调整年龄、BMI、ASA 评分、机械和抗生素肠道准备、急症手术、种族、性别、吸烟状况、高血压和糖尿病。分析的结果包括术后 90 天内开始化疗的比率、采集的淋巴结数量、术中或术后输血的任何发生情况以及造口的需求。在研究期间,44745 名患者接受了微创结肠癌切除术;腹腔镜组 39614 例,机器人组 7831 例。在调整混杂因素后,机器人结直肠切除术与 90 天内开始化疗的可能性显著增加相关(RR 1.98,95%CI{1.86-2.10},p<0.001)。机器人治疗的患者采集的淋巴结明显更多,术中或术后输血的需求显著减少(RR 0.64,95%CI{0.57-0.71},p<0.001),造口形成的需求显著降低(RR 0.26,95%CI{0.22-0.30},p<0.001)。由于这是一项回顾性和非随机研究,可能存在残留的偏倚和混杂变量。该研究还存在编码不完整和不准确的问题。我们也没有关于可能影响化疗时间的其他因素的额外信息。此外,没有关于外科医生或医院数量的信息,而这些因素可能与结果相关。与腹腔镜结直肠切除术相比,机器人结直肠切除术在 90 天内开始化疗的比率显著提高,输血需求显著减少,接受造口术的可能性降低,从而在短期内在肿瘤学结果方面取得了显著的进展。